{"id":988408,"date":"2026-08-03T09:34:17","date_gmt":"2026-08-03T13:34:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/"},"modified":"2026-08-03T09:34:17","modified_gmt":"2026-08-03T13:34:17","slug":"taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/","title":{"rendered":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug.  03, 2026  (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha\u2019s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha\u2019s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval.<\/p>\n<p>Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand. Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products.<\/p>\n<p>\u201cAs we continue to advance TSHA-102, establishing long-term commercial manufacturing capacity is a critical component of our launch readiness strategy,\u201d said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. \u201cCatalent&#8217;s deep gene therapy expertise and proven commercial manufacturing capabilities make them an ideal partner as we expand our partnership to further strengthen our commercial infrastructure with a reliable, scalable supply framework. With BLA-enabling Process Performance Qualification activities underway, we believe we have established the manufacturing foundation necessary to support the strong demand we expect following the potential launch and commercialization of TSHA-102.\u201d<\/p>\n<p>\u201cAt Catalent, our priority is to support innovators who are redefining what\u2019s possible for patients with rare diseases,\u201d said David McErlane, Biologics Group President for Catalent. \u201cOur partnership with Taysha brings together deep AAV expertise and a shared commitment to advancing a potential therapy for Rett syndrome\u2014a condition with significant unmet need. We are proud to help enable the development and future supply of therapies that have the potential to make a meaningful difference for patients and their families.\u201d<\/p>\n<p>This partnership reflects Catalent\u2019s continued commitment to supporting innovators across the cell and gene therapy landscape, providing end-to-end solutions from development through commercialization to help bring transformative therapies to patients.<\/p>\n<p>\n        <strong>About Rett Syndrome<\/strong><br \/>\n        <br \/>Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked\u00a0<em>MECP2<\/em>\u00a0gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and\/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic\/likely pathogenic\u00a0<em>MECP2\u00a0<\/em>mutation is estimated to affect between 15,000 and 20,000 patients in the\u00a0U.S., EU, and\u00a0U.K.<\/p>\n<p>\n        <strong>About Taysha Gene Therapies<\/strong><br \/>\n        <br \/>Taysha Gene Therapies\u00a0(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company\u2019s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yfvM-rkUPjcu5cIfvND8tMZh6RWPbbFlWV2p71PP5_saaHVDACtw4HzJfGlKC9B3GqJ2gpILFWk2lZF23lUarGnnDvN8VBKC4xGuwu1UjZrhsy2E-R5hWoK4uKDX0ZT2pjV35GuhGkQfw-_yrEOmgFemsQLqzzmuIfxZXitEcUht-vTVhdl2VcOk7OE_LgwTpbykkT44lcRGU4deGLIbVuZA-WMFqsHJEsJJ1iwvaNuY4aIUXnPxXh9JQqFogIjdLvCikPfLKDe3uMN8oo4lLA==\" rel=\"nofollow\" target=\"_blank\">www.tayshagtx.com<\/a>.<\/p>\n<p>\n        <strong>About Catalent<\/strong><br \/>\n        <br \/>Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers\u2019 needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K-GgYIRdx5qUOlqGY_cMkqAmr1a78lcrXj90dgigwz47Ab8lTey0mC4VVhQOMsDkMnNtqgrpUAfY1xNsU6S7UfzJdFA1Ofz272P9QI9kcQs=\" rel=\"nofollow\" target=\"_blank\">www.catalent.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cprojects,\u201d \u201cplans,\u201d and \u201cfuture\u201d or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102 and Taysha\u2019s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha\u2019s research, development and regulatory plans for its product candidates; the potential demand for TSHA-102; and the ability of the agreement between Taysha and Catalent to secure long-term commercial manufacturing capacity and a scalable supply framework for the commercial supply of TSHA-102. Forward-looking statements are based on management\u2019s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha\u2019s business are described in detail in its SEC filings, including in Taysha\u2019s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is available on the SEC\u2019s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.<\/p>\n<p>\n        <strong>Taysha Company Contact:<\/strong><br \/>\n        <br \/>Hayleigh Collins<br \/>Senior Director, Corporate Communications and Investor Relations<br \/>Taysha Gene Therapies, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_8Bgmyo_DK_NXhQSfJ-Jr1_KIVyZZwhZy1rJAZ0sAoRhC2jTqxKmWfxJooNGLpBMScNnpTO8tCfYypnE3hpLcRvXXo5yCw2_U_uZWgNA7HWHRtHAJCV8_PdiZ6nxersO7_ZAGBiQKUFKONjgE1My_QaoD2u5QNOe4hssG2UDGnV6dCaNTKSbUnUuVsC8ZJ16jy4VhJpeVdJUbkyMwfk8e7YQdhTzB8oH4vqcUW9hYz1dylR0lzOBMuo9CUYuRgD82qMK2pz2Hf-qIXpvYd_wyw==\" rel=\"nofollow\" target=\"_blank\">hcollins@tayshagtx.com<\/a><\/p>\n<p>\n        <strong>Taysha Media Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uC6Z-QS06xF_UIlhqHMTMGOcNg0-GUHwJjqyOFZv6jz9W8ECOcLSz-T0CqgfpCJWknEPFiG8o-ZJWzHjD0nFDd1i3lQp1XtJrv8cw-GfPvw=\" rel=\"nofollow\" target=\"_blank\">media@tayshagtx.com<\/a>\n      <\/p>\n<p>\n        <strong>Catalent Media Contact:<\/strong><br \/>\n        <br \/>media@catalent.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTFhZWIzMGUtMzRlZC00Yzc1LWE5NTEtMDYzYWE3ZTM2MDMwLTEyMTM5NjYtMjAyNi0wOC0wMy1lbg==\/tiny\/Taysha-Gene-Therapies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha\u2019s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha\u2019s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval. Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988408","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha\u2019s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha\u2019s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval. Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity &hellip; Continue reading &quot;Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T13:34:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome\",\"datePublished\":\"2026-08-03T13:34:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/\",\"name\":\"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\",\"datePublished\":\"2026-08-03T13:34:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk","og_description":"CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha\u2019s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha\u2019s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval. Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity &hellip; Continue reading \"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T13:34:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome","datePublished":"2026-08-03T13:34:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/","name":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=","datePublished":"2026-08-03T13:34:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMTg4MiM3NzUzODM0IzIyMDI0MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988408"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988408\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}